N-(4-(4-fluorophenyl)-5-methylthiazol-2-yl)benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-(4-fluorophenyl)-5-methylthiazol-2-yl)benzamide
• 英文别名: N-[4-(4-fluorophenyl)-5-methyl-1,3-thiazol-2-yl]benzamide
• 化学式: C₁₇H₁₃FN₂OS
• 分子量: 312.367
• InChiKey: XTSIZFXZDVVQFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  70.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(4-(4-fluorophenyl)-5-methylthiazol-2-yl)benzamide 、 碘甲烷 在 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 2.33h， 生成 N-(4-(4-fluorophenyl)-3,5-dimethylthiazol-2(3H)-ylidene)benzamide 、 N-(4-(4-fluorophenyl)-5-methylthiazol-2-yl)-N-methylbenzamide
  参考文献：
  名称：

  噻唑衍生物作为转移性癌细胞迁移和侵袭的新型抑制剂的修饰和生物学评价

  摘要：

  Fascin 最近已成为潜在的治疗靶点，因为它在癌细胞中的表达与肿瘤进展和转移密切相关。在最初发现一系列通过可能抑制肌成束蛋白功能而表现出有效抗迁移和抗侵袭活性的噻唑衍生物之后，我们在此报告了 63 种新型噻唑衍生物的设计和合成，通过进一步的结构修饰来寻找更有效的肌成束蛋白抑制剂。在噻唑氮上具有更长烷基链取代的5系列类似物比具有其他结构基序的类似物表现出更大的抗迁移活性。最强大的模拟，5p，在 24 nM 时抑制了 50% 的细胞迁移。此外，噻唑类似物显示出很强的抗血管生成活性，在鸡胚胎膜试验中阻断了新血管的形成。最后，进行了一项功能研究，以通过与 F-肌动蛋白捆绑蛋白肌成束蛋白的相互作用来研究作用机制。

  DOI：

  10.1021/jm500724x
• 作为产物：
  描述：

  苯甲酰氯 、 4-(4-氟苯基)-5-甲基噻唑-2-胺 在 4-二甲氨基吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 N-(4-(4-fluorophenyl)-5-methylthiazol-2-yl)benzamide
  参考文献：
  名称：

  噻唑衍生物作为转移性癌细胞迁移和侵袭的新型抑制剂的修饰和生物学评价

  摘要：

  Fascin 最近已成为潜在的治疗靶点，因为它在癌细胞中的表达与肿瘤进展和转移密切相关。在最初发现一系列通过可能抑制肌成束蛋白功能而表现出有效抗迁移和抗侵袭活性的噻唑衍生物之后，我们在此报告了 63 种新型噻唑衍生物的设计和合成，通过进一步的结构修饰来寻找更有效的肌成束蛋白抑制剂。在噻唑氮上具有更长烷基链取代的5系列类似物比具有其他结构基序的类似物表现出更大的抗迁移活性。最强大的模拟，5p，在 24 nM 时抑制了 50% 的细胞迁移。此外，噻唑类似物显示出很强的抗血管生成活性，在鸡胚胎膜试验中阻断了新血管的形成。最后，进行了一项功能研究，以通过与 F-肌动蛋白捆绑蛋白肌成束蛋白的相互作用来研究作用机制。

  DOI：

  10.1021/jm500724x

文献信息

• Thiazole compounds and methods of use
  申请人：Zhang Suoming

  公开号：US20070004711A1

  公开（公告）日：2007-01-04

  The present invention provides compounds, salts and hydrates of Formula I, wherein the variables Ar 1 , R 2 , R 3 , R 4 , r, q, and t are defined herein. Certain compounds of Formula I described herein possess potent antiviral activity. The invention also provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. Certain compounds described herein inhibit assembly of the HCV replication complex. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.
• THIAZOLE COMPOUNDS AND METHODS OF USE
  申请人：Zhang Suoming

  公开号：US20120108576A1

  公开（公告）日：2012-05-03

  The present invention provides compounds, salts and hydrates of Formula I, wherein the variables Ar 1 , R 2 , R 3 , R 4 , r, q, and t are defined herein. Certain compounds of Formula I described herein possess potent antiviral activity. The invention also provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. Certain compounds described herein inhibit assembly of the HCV replication complex. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.
• ANTI-MIGRATION AND ANTI-INVASION THIAZOLE ANALOGS FOR TREATMENT OF CELLULAR PROLIFERATIVE DISEASE
  申请人：XAVIER UNIVERSITY OF LOUISIANA

  公开号：US20150274714A1

  公开（公告）日：2015-10-01

  Thiazole analog compounds and their pharmaceutically acceptable salts are disclosed, including pharmaceutical compositions comprising the thiazole analog compounds, either alone or in combination with at least one additional therapeutic agent, and/or with a pharmaceutically acceptable carrier. Methods of using the thiazole analog compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cellular proliferative diseases, such as cancer, are also disclosed.
• FASCIN BINDING COMPOUNDS FOR SPINOGENESIS
  申请人：SPINOGENIX, INC.

  公开号：US20210330646A1

  公开（公告）日：2021-10-28

  In some embodiments, a method of promoting spinogenesis in a patient is provided, comprising administering to a patient in need thereof a therapeutically effective amount of a compound which binds to fascin at least at binding site 2 or binding site 3.
• US8088806B2
  申请人：——

  公开号：US8088806B2

  公开（公告）日：2012-01-03